Comparable peri‐transplant mortality and incidence of febrile neutropenia after high‐dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as outpatient versus inpatient

Documenti analoghi

• Busulfan, melphalan and carfilzomib high‐dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma
  di: Patrick Hagen, et al.
  Pubblicazione: (2024)
• Outcomes of frail patients undergoing high‐dose chemotherapy and autologous stem cell transplantation for multiple myeloma
  di: Stephanie Yohay, et al.
  Pubblicazione: (2024)
• A rare complication during autologous stem cell transplantation in multiple myeloma
  di: Valeria Tomarchio, et al.
  Pubblicazione: (2025)
• Reduced‐intensity conditioning with fludarabine/busulfan versus fludarabine/low‐dose melphalan in patients with non‐Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation
  di: Kimimori Kamijo, et al.
  Pubblicazione: (2024)
• Late infections after high‐dose therapy and autologous stem cell transplantation for lymphoma: A Danish population‐based study
  di: Freja Tang Severinsen, et al.
  Pubblicazione: (2025)